The results showed that pretreatment proportion of CD8+CD28− T cells in CD8 T cell can serve as a new prognostic biomarker for NPC after radiotherapy, and the nomograms we developed have good predictive value for progression-free survival (PFS) and distant metastasis-free survival (DMFS). This evidence concerns the gene CD8A and nasopharyngeal carcinoma.